Disease Landscape and Forecast Insights

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted…

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…

MARKET OUTLOOK With the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s…

The increasingly crowded RA market boasts many different targeted agents representing several distinct drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including…

The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s…

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…

MARKET OUTLOOK The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, together with conventional treatments, makes…

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…